Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: efficacy, safety, and tolerability
- PMID: 32709290
- DOI: 10.1016/j.kint.2020.03.023
Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: efficacy, safety, and tolerability
Comment in
-
A tolvaptan skeptic repents.Kidney Int. 2020 Aug;98(2):293. doi: 10.1016/j.kint.2020.04.005. Kidney Int. 2020. PMID: 32709291 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
